Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472378 | 1.00 | EPAS1 (0.37) | EPAS1GRM5 | |
| SCHEMBL28264132 | 0.86 | EPAS1 (0.36) | EPAS1GRM5 | |
| SCHEMBL2161087 | 0.84 | VCAM1 (0.38) | — | |
| SCHEMBL29951645 | 0.84 | VCAM1 (0.38) | — | |
| SCHEMBL29965999 | 0.81 | ALDH1A1 (0.35) | EPAS1 | |
| SCHEMBL18345851 | 0.81 | ALDH1A1 (0.35) | EPAS1 | |
| SCHEMBL18345853 | 0.81 | ALDH1A1 (0.35) | EPAS1 | |
| SCHEMBL16412295 | 0.79 | GRM5 (0.35) | GRM5 | |
| SCHEMBL5222304 | 0.79 | GRM5 (0.35) | GRM5 | |
| SCHEMBL31653367 | 0.79 | EGFR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-28 | — | — | US | disclosed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-04-17 | — | — | US | disclosed |
| US-12208110-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2025011546-A1 | HUMAN CASEINOLYTIC PROTEASE P AGONISTS AND USES THEREOF | ACELON THERAPEUTICS (CN) | 2025-01-16 | — | — | WO | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | SIRONAX LTD (KY) | 2024-10-29 | — | — | US | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2137181-B1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LTD (GB) | 2011-03-02 | — | — | EP | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| EP-2137181-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008128951-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | CTRL, PTMS, DDT | EPAS1 3923/4885GRM5 516/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | EPAS1 3864/4885GRM5 3160/4885 |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | EPAS1 2258/4885GRM5 2627/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | EPAS1 2258/4885GRM5 2627/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | EPAS1 2046/4885GRM5 2340/4885 |
| US-12208110-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS1, SGMS2 | EPAS1 1361/4885GRM5 1843/4885 |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | RIPK1, RIPK3, RIPK4 | EPAS1 373/4885GRM5 3914/4885 |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | EPAS1 422/4885GRM5 986/4885 |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | S1PR1, S1PR3, S1PR2 | EPAS1 993/4885GRM5 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.